Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms TUXEDO-1
- 10 May 2023 Status changed from active, no longer recruiting to completed.
- 13 Mar 2023 Planned primary completion date changed from 28 Jul 2022 to 28 Jul 2023.
- 13 Sep 2022 Results assessing quality-of-life and neurocognitive function presented at the 47th European Society for Medical Oncology Congress